Recent Updates
Recently added Catalysts

VSJ-110

Phase 2

Dry Eye | Small molecule | Ophthalmology |Vanda Pharmaceuticals Inc.|Last Updated: Sep 17, 2025

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindPLACEBO_CONTROLLED
Total Trials1
Total Enrollment160
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT07179055An Eight-Week Study to Evaluate the Safety and Efficacy of VSJ-110 Compared to Placebo in the Treatment of Dry EyePHASE2 RECRUITING 160Oct 1, 2025Sep 1, 2026Sep 17, 20255 United States
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Corneal Staining
Measured over an 8-week treatment period

Corneal Staining will be assessed by the investigator on a scale of 0-4, with a higher number indicating a higher grade of staining.

Secondary Endpoints
Schirmer's Tear Test
Measured over an 8-week treatment period
Eye Dryness Score (EDS) of the Visual Analogue Scale (VAS)
Measured over an 8-week treatment period
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingQUADRUPLE
ModelPARALLEL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
VSJ-110 SolutionEXPERIMENTAL -
Placebo SolutionPLACEBO_COMPARATOR -
Interventions
NameTypeDescription
VSJ-110DRUGophthalmic solution
PlaceboDRUGophthalmic solution
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — N/A
SexALL
Healthy VolunteersNo
Study Sites5

Inclusion Criteria: * Be at least 18 years of age of either gender and any race. * Provide written informed consent and sign the HIPAA form. * Be willing and able to follow all instructions and attend all study visits. Exclusion Criteria: * Use of any of the disallowed medications during the wash...

Countries:United States
Unlock Eligibility Criteria
Recent Changes (Last 90 Days)
LOWMay 26, 2026NCT07179055primaryCompletionDate: changed
LOWMay 24, 2026NCT07179055studyFirstPostDate: changed